Tenomix is transforming pathology automation by uniting robotics, ultrasound imaging, and AI at the benchtop—an industry first. Their first product application focuses on the lymph node (LN) dissection process, which is essential for measuring cancer spread, yet it is still manually performed worldwide at an error rate of over 50%. Tenomix’s flagship device is designed to streamline and guide LN identification, subsequently helping pathology labs optimize workflow, conserve resources, and enhance overall consistency in tissue evaluation.

Backed by a multidisciplinary team of engineers, clinicians, investors, and business leaders, Tenomix is forging strategic partnerships with leading healthcare providers and research institutions to refine and validate its novel approach. By innovating the LN dissection process, Tenomix aims to support pathology teams worldwide in their mission to improve cancer staging—ultimately empowering better-informed decisions in patient care.